Showing 1 to 2 of 2 results


Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Progress
36% Bias Score

Walgreens Considers Breakup, Bucking Healthcare Consolidation Trend
Walgreens Boots Alliance is considering splitting into three companies: Boots UK, U.S. retail pharmacies, and a specialty pharmacy, diverging from the healthcare consolidation trend exemplified by CVS Health's integrated model. This follows Walgreens' financial losses and struggles with its VillageM...

Walgreens Considers Breakup, Bucking Healthcare Consolidation Trend
Walgreens Boots Alliance is considering splitting into three companies: Boots UK, U.S. retail pharmacies, and a specialty pharmacy, diverging from the healthcare consolidation trend exemplified by CVS Health's integrated model. This follows Walgreens' financial losses and struggles with its VillageM...
Progress
48% Bias Score
Showing 1 to 2 of 2 results